G2-T (Tirz) represents a significant advancement in metabolic research, positioned as a dual-agonist compound engineered to engage two primary incretin pathways—GLP-1 and GIP receptors. This dual-pathway design builds upon earlier single-agonist frameworks, offering enhanced regulatory control within energy intake, glucose-related signaling, and adipose metabolism research models.
Through coordinated receptor engagement, G2-T is structured to support more efficient metabolic signaling than first-generation incretin compounds, making it a key developmental step in research optimization.
Dual activation of GLP-1 and GIP receptor pathways
Enhanced regulation of energy intake–associated signaling
Improved glucose utilization and insulin-related pathway efficiency
Support for metabolic balance during adaptive plateaus
Demonstrated advancement over single-agonist models in comparative studies
G2-T functions as a dual incretin receptor agonist, simultaneously activating GLP 1 and GIP signaling pathways. These pathways are central to metabolic regulation research and influence glucose-dependent signaling, energy intake modulation, and lipid storage dynamics.
By integrating both receptor actions into a single molecular structure, G2-T demonstrates greater signaling efficiency than GLP 1–only compounds such as G1-S. Comparative research has shown improved outcomes across multiple metabolic markers, including adipose-related measurements and glucose-associated endpoints, highlighting its role as an intermediary advancement between single- and triple-agonist development.
Compound Type: Dual-agonist compound
Classification: GLP-1 / GIP receptor agonist
Administration Route: Subcutaneous (weekly protocols observed in studies)
Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight: ~4,813.03 g/mol
Estimated Half-Life: ~5 days
Development Status: Advanced clinical research
Research Focus: Metabolic signaling, glucose regulation pathways, adipose modulation
SlimFit Compounds partners with emerging U.S.-based manufacturers that adhere to strict production, verification, and purity standards. These research-grade formulations are produced using protocols comparable to those employed by major pharmaceutical laboratories, enabling access to high-quality compounds without excessive cost barriers.
This product is intended for research and laboratory use only.
Not for human consumption.
Not intended to diagnose, treat, cure, or prevent any disease.
Information provided is for educational and research reference purposes only and has not been evaluated by the FDA. Only qualified professionals should handle this compound in appropriate research or laboratory settings.
G2-T (Tirz) represents a significant advancement in metabolic research, positioned as a dual-agonist compound engineered to engage two primary incretin pathways—GLP-1 and GIP receptors. This dual-pathway design builds upon earlier single-agonist frameworks, offering enhanced regulatory control within energy intake, glucose-related signaling, and adipose metabolism research models.
Through coordinated receptor engagement, G2-T is structured to support more efficient metabolic signaling than first-generation incretin compounds, making it a key developmental step in research optimization.
Dual activation of GLP-1 and GIP receptor pathways
Enhanced regulation of energy intake–associated signaling
Improved glucose utilization and insulin-related pathway efficiency
Support for metabolic balance during adaptive plateaus
Demonstrated advancement over single-agonist models in comparative studies
G2-T functions as a dual incretin receptor agonist, simultaneously activating GLP 1 and GIP signaling pathways. These pathways are central to metabolic regulation research and influence glucose-dependent signaling, energy intake modulation, and lipid storage dynamics.
By integrating both receptor actions into a single molecular structure, G2-T demonstrates greater signaling efficiency than GLP 1–only compounds such as G1-S. Comparative research has shown improved outcomes across multiple metabolic markers, including adipose-related measurements and glucose-associated endpoints, highlighting its role as an intermediary advancement between single- and triple-agonist development.
Compound Type: Dual-agonist compound
Classification: GLP-1 / GIP receptor agonist
Administration Route: Subcutaneous (weekly protocols observed in studies)
Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight: ~4,813.03 g/mol
Estimated Half-Life: ~5 days
Development Status: Advanced clinical research
Research Focus: Metabolic signaling, glucose regulation pathways, adipose modulation
SlimFit Compounds partners with emerging U.S.-based manufacturers that adhere to strict production, verification, and purity standards. These research-grade formulations are produced using protocols comparable to those employed by major pharmaceutical laboratories, enabling access to high-quality compounds without excessive cost barriers.
This product is intended for research and laboratory use only.
Not for human consumption.
Not intended to diagnose, treat, cure, or prevent any disease.
Information provided is for educational and research reference purposes only and has not been evaluated by the FDA. Only qualified professionals should handle this compound in appropriate research or laboratory settings.
